GNI Group Ltd. (2160.T) JPX

2,631.00

+51(+1.98%)

Updated at June 03 02:58PM

Currency In JPY

GNI Group Ltd.

Address

Nihonbashi-Honcho YS Building

Tokyo, 103-0023

Japan

Phone

81 3 6214 3600

Website

https://www.gnipharma.com

Sector

Healthcare

Industry

Biotechnology

Employees

867

First IPO Date

August 31, 2007

Key Executives

Name	Title	Pay	Year Born
Ying Luo	Chief Executive Officer, President, Representative Executive Officer & Chair	76M	1965
Zhang Ping	Executive Officer & Director	49M	1973
Stephen Charnock-Jones	Co-Founder	0	N/A
Ryosuke Matsui	Executive Officer, VP, COO, CFO & Director	0	1979
Kan-ichiro Suzuki	Vice President & Executive Officer	0	1954
Takuya Kaneko	Executive Officer, CSO, GM of Administration Div, Head of Grp Alliance Prom Office	0	N/A
Cristin Print	Co-Founder	0	N/A
Kazuhiro Kawauchi	Executive Officer & Chief Business Development Officer	0	1962
Kosuke Tashiro	Co-Founder	0	N/A

Description

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.